Telix to Host R&D Day in New York City on September 22, 2026
Telix today advises that it will host a Research and Development (R&D) Day on Tuesday, September 22, 2026, from 8:30 a.m. to 12:30 p.m. EDT in New York City.
Telix H1 2026 Results: Investor Webcast Notification
Telix today advises that it will release its financial results for the half-year ended June 30, 2026 on Thursday August 20, 2026.
EJNMMI Research: TLX400-Tx Shows Encouraging Disease Control in Medullary Thyroid Cancer
Telix today announces publication of long‑term clinical outcomes from an investigator‑led study evaluating TLX400‑Tx, its lead fibroblast activation protein (FAP)-targeted therapy candidate, in patients with advanced or metastatic medullary thyroid carcinoma (MTC).
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
Telix today announced publication of results from the ProstACT SELECT study in Cancers, a peer-reviewed journal. The Phase 1 study evaluated TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan), Telix’s first-in-class prostate-specific membrane antigen (PSMA) targeting radio antibody-drug conjugate (rADC) therapy candidate. The study’s scientific purpose was to evaluate lesion concordance between 68Ga-PSMA-PET[5] and multi-time point SPECT[6] imaging for patient selection using a “theranostic” approach.
PSMA-PET imaging for prostate cancer: Exploring gallium-68 in clinical practice
Telix spoke with a panel of global experts to examine the rapid evolution of gallium-68 (68Ga) PSMA-PET imaging in prostate cancer and to ask where the technology goes next.
Telix Q2 2026 Revenue US$247M, Strong Momentum and Pipeline Progress
Telix provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026).
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Txfor Renal Cancer
Telix today announced that the first patient has been dosed with TLX250-Tx (lutetium-177 (177Lu) girentuximab tetraxetan)in the LUTEON study, the first radiopharmaceutical therapy to enter Phase 3 development for ccRCC. LUTEON is a randomized, prospective, open label, multi-center study evaluating a CAIX-targeting radionuclide therapy in patients with relapsed or recurrent ccRCC.
Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study
Telix today announced completion of patient enrollment in the pivotal Phase 3 registration study of TLX591-Px (Illuccix®, Kit for the preparation of 68Ga-PSMA-11[1]) for prostate cancer imaging in Japanese patients.
Telix Opens Australian-First Facility to Accelerate Delivery of New Cancer Treatments and Expand Sovereign Manufacturing
Telix today officially opens a multi-million dollar radiopharmaceutical research, manufacturing and treatment facility in Melbourne, expanding and strengthening Australia’s capability in one of the world’s fastest-growing areas of cancer diagnosis and treatment.
First Patients Dosed in Optimal-e Trial for Earlier Stage Prostate Cancer
Telix and St Vincent’s Hospital today announced that the first patients have been dosed with TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) in the OPTIMAL-e trial, led by Professor Louise Emmett for patients with metastatic hormone-sensitive prostate cancer (mHSPC) at St Vincent’s Hospital in Sydney, Australia.